Civitas commences CVT-301 Phase 2a trial in Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS(TM) respiratory delivery platform, announced today the initiation of a Phase 2a clinical trial in Parkinson's disease patients evaluating CVT-301, an inhaled formulation of levodopa (L-dopa), for the rapid relief from motor fluctuations. CVT-301 provides immediate onset of a large and precise dose of L-dopa.    

"Consistent with our commitment to rapidly develop important new therapies for patients, we demonstrated pharmacokinetic proof-of-concept for CVT-301 in less than 12 months from launching Civitas and are now initiating this Phase 2a study in Parkinson's patients," said Dr. Martin Freed, Chief Medical Officer and co-founder of Civitas. "Leveraging the ARCUS platform along with the 40 years of existing L-dopa clinical experience we hope to provide Parkinson's patients with a new therapy enabling improved management of their motor fluctuations."

The Phase 2a study is a randomized, placebo-controlled, single dose, cross-over design that will characterize the safety and tolerability of CVT-301 and evaluate pharmacodynamic effects and L-dopa pharmacokinetics in patients with Parkinson's disease with motor fluctuations ("off episodes"). This Phase 2a study is designed to establish the dose for future clinical trials with CVT-301. Patients will receive oral Sinemet®, inhaled placebo and CVT-301 which will be followed by serial evaluations of L-dopa pharmacokinetics, motor response and safety at each visit. Twenty-four (24) patients will be enrolled.


Civitas Therapeutics, Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Researchers identify chemical compound that may short-circuit brain cell death in Parkinson's disease